The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
The CAPItello-280 castrate-resistant prostate cancer trial is discontinued early.
The same trial that sent Summit up 272% sees the stock crash 36%.
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
But sasanlimab's use looks set to remain narrow.